NEW YORK (360Dx) – Angle this week announced its preliminary financial results for the fiscal year ended April 30. The liquid biopsy company reported revenues increased to £700,000 ($917,847) from £500,000 in 2017. The firm's loss for the year widened to £7.5 million from £6.4 million, reflecting planned investment to develop and validate clinical application and commercial use of the Parsortix system.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.